# Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy

> **NCT01928511** · PHASE4 · COMPLETED · sponsor: **Seng Gee Lim** · enrollment: 254 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly
- **DRUG:** Nucleos(t)ide analogue therapy

## Key facts

- **NCT ID:** NCT01928511
- **Lead sponsor:** Seng Gee Lim
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928511, "Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01928511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*